News & Updates
Showing Pharmacy articles
Showing
Palbociclib plus ET prolongs survival in metastatic breast cancer
First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.
T-DXd improves PFS in breast cancer with rapid progression
Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.
How safe is sacubitril-valsartan plus spironolactone for ADHF?
Initiation of sacubitril-valsartan with spironolactone during hospitalization for acute decompensated heart failure (ADHF) does not result in more adverse drug reactions (ADRs), reports a study. However, patients on this regimen tend to develop hyperkalemia.
Corticosteroids lessen mechanical ventilation use in CAP
In critically ill patients with community-acquired pneumonia (CAP), treatment with corticosteroids has significantly reduced the need for mechanical ventilation, while use of hydrocortisone has prevented many hospital deaths.